AtriCure, Inc. develops, manufactures, and sells devices for the surgical ablation of cardiac tissue and systems to medical centers in the United States, Europe, Asia, and internationally. More Details
Adequate balance sheet with concerning outlook.
Share Price & News
How has AtriCure's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: ATRC is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 5% a week.
Volatility Over Time: ATRC's weekly volatility (5%) has been stable over the past year.
7 Day Return
US Medical Equipment
1 Year Return
US Medical Equipment
Return vs Industry: ATRC exceeded the US Medical Equipment industry which returned 37.4% over the past year.
Return vs Market: ATRC exceeded the US Market which returned 53.9% over the past year.
Long-Term Price Volatility Vs. Market
How volatile is AtriCure's share price compared to the market and industry in the last 5 years?
Simply Wall St News
2 months ago | Simply Wall StThe AtriCure (NASDAQ:ATRC) Share Price Has Gained 290%, So Why Not Pay It Some Attention?
3 months ago | Simply Wall StDoes AtriCure (NASDAQ:ATRC) Have A Healthy Balance Sheet?
3 months ago | Simply Wall StHow Should Investors React To AtriCure's (NASDAQ:ATRC) CEO Pay?
Is AtriCure undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: ATRC ($68) is trading above our estimate of fair value ($1.91)
Significantly Below Fair Value: ATRC is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: ATRC is unprofitable, so we can't compare its PE Ratio to the US Medical Equipment industry average.
PE vs Market: ATRC is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate ATRC's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: ATRC is overvalued based on its PB Ratio (7.5x) compared to the US Medical Equipment industry average (5.1x).
How is AtriCure forecast to perform in the next 1 to 3 years based on estimates from 8 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: ATRC is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: ATRC is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: ATRC is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: ATRC's revenue (15.8% per year) is forecast to grow faster than the US market (9.3% per year).
High Growth Revenue: ATRC's revenue (15.8% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: ATRC is forecast to be unprofitable in 3 years.
How has AtriCure performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: ATRC is currently unprofitable.
Growing Profit Margin: ATRC is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: ATRC is unprofitable, and losses have increased over the past 5 years at a rate of 6.1% per year.
Accelerating Growth: Unable to compare ATRC's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ATRC is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (10.1%).
Return on Equity
High ROE: ATRC has a negative Return on Equity (-11.68%), as it is currently unprofitable.
How is AtriCure's financial position?
Financial Position Analysis
Short Term Liabilities: ATRC's short term assets ($306.7M) exceed its short term liabilities ($49.1M).
Long Term Liabilities: ATRC's short term assets ($306.7M) exceed its long term liabilities ($253.0M).
Debt to Equity History and Analysis
Debt Level: ATRC's debt to equity ratio (14.6%) is considered satisfactory.
Reducing Debt: ATRC's debt to equity ratio has increased from 0% to 14.6% over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: ATRC has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if ATRC has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
What is AtriCure current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate ATRC's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate ATRC's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if ATRC's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if ATRC's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of ATRC's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Mike Carrel (49 yo)
Mr. Michael H. Carrel, also known as Mike, serves as the Chief Executive Officer and President of AtriCure, Inc. at Endoscopic Technologies, Inc. since November 2012. Mr. Carrel has been Director since Feb...
CEO Compensation Analysis
Compensation vs Market: Mike's total compensation ($USD5.83M) is about average for companies of similar size in the US market ($USD5.13M).
Compensation vs Earnings: Mike's compensation has increased whilst the company is unprofitable.
Experienced Management: ATRC's management team is considered experienced (4.6 years average tenure).
Experienced Board: ATRC's board of directors are considered experienced (7.6 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 13.8%.
AtriCure, Inc.'s company bio, employee growth, exchange listings and data sources
- Name: AtriCure, Inc.
- Ticker: ATRC
- Exchange: NasdaqGM
- Founded: 2000
- Industry: Health Care Equipment
- Sector: Healthcare
- Market Cap: US$2.865b
- Shares outstanding: 45.63m
- Website: https://www.atricure.com
Number of Employees
- AtriCure, Inc.
- 7555 Innovation Way
- United States
AtriCure, Inc. develops, manufactures, and sells devices for the surgical ablation of cardiac tissue and systems to medical centers in the United States, Europe, Asia, and internationally. It offers Isolat...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/04/16 23:47|
|End of Day Share Price||2021/04/16 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.